Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$90.05

0.48 (0.54%)

06:54
07/19/18
07/19
06:54
07/19/18
06:54

Eli Lilly updates Trulicity label to show efficacy in CKD, include AWARD-7 trial

The U.S. label for Eli Lilly's once-weekly Trulicity is updated to show the medicine's safety and efficacy in people with type 2 diabetes who have moderate to severe chronic kidney disease, or CKD. The label now includes data from the AWARD-7 clinical trial, which showed that people treated with Trulicity 1.5 mg or 0.75 mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss, compared to those treated with traditional basal-bolus insulin. Trulicity is a once-weekly glucagon-like peptide-1, or GLP-1, receptor agonist, or RA, injectable prescription medicine to improve blood sugar in adults with type 2 diabetes. AWARD-7 results showed that at 26 and 52 weeks, both Trulicity doses plus mealtime insulin lispro provided similar glycemic control to insulin glargine plus mealtime insulin lispro. All treatment groups had between a 1%-2%reduction in A1C from baseline at both endpoints. At the 26-week primary endpoint, up to 78% of all study participants across each treatment group reached target A1C levels of less than 8%; at 52 weeks, approximately 70% achieved those results.

  • 24

    Jul

  • 10

    Sep

LLY Eli Lilly
$90.05

0.48 (0.54%)

07/17/18
MZHO
07/17/18
INITIATION
Target $26
MZHO
Buy
Mizuho starts Xeris Pharmaceuticals with Buy rating, $26 target
Mizuho analyst Difei Yang last night initiated coverage of Xeris Pharmaceuticals with a Buy rating and $26 price target. The company offers a potentially superior solution for the treatment of severe hypoglycemia compared to the standard of care - Eli Lilly's (LLY) glucagon emergency kit, Yang told investors in a research note. The analyst sees a "significant growth opportunity" for the ready-to-use glucagon rescue pen as more healthcare professionals prescribe an easier option for patients with diabetes at risk of severe hypoglycemia.
07/17/18
CANT
07/17/18
NO CHANGE
CANT
Overweight
Aclaris offers best risk/reward of hair loss players, says Cantor Fitzgerald
The potential for JAK inhibitors to treat alopecia areata may be underappreciated by investors because the Street does not appear to be ascribing enough value to the opportunity, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. Of the three companies she covers developing JAKs for hair loss, Aclaris Therapeutics (ACRS), Eli Lilly (LLY) and Pfizer (PFE), the analyst believes Aclaris offers the best risk/reward and greatest upside potential. The company has a market cap below $700M and two potential "shots on goal" for alopecia areata, Chen writes. She estimates combined peak sales of $1B-plus for both opportunities and keeps an Overweight rating on Aclaris. The physicians the analyst spoke to believe the company's JAKs for hair loss will work.
07/18/18
PIPR
07/18/18
NO CHANGE
Target $450
PIPR
Overweight
Piper maintains Overweight on Regeneron on tanezumab news
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Regeneron Pharmaceuticals (REGN) on news that tanezumab, Pfizer (PFE) and Eli Lilly's (LLY) anti-NGF antibody that is a competitor to Regeneron's fasinumab, successfully completed the first of several Phase 3 trials. Fasinumab remains an unmodeled opportunity, but the read-through from tanezumab is positive and the market for an effective, non-opioid chronic pain treatment is "massive," Raymond tells investors in a research note. The analyst points out that Regeneron and Teva (TEVA) still expect to report Phase 3 data starting later this year. Raymond keeps an Overweight rating on Regeneron with a $450 price target.
07/18/18
WELS
07/18/18
NO CHANGE
WELS
Novartis report has negative read through for Teva, Mylan, says Wells Fargo
Wells Fargo analyst David Maris noted that Novartis (NVS) lowered its 2018 guidance for Sandoz along with its Q2 report and reportedly told Bloomberg that it would consider selling the generic drug unit. He sees a negative read through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL), from Novartis' report, Maris tells investors. He also noted that Novartis said it will not increase prices on its drugs in the U.S. for the rest of 2018, as Pfizer (PFE) recently has also said, calling this "a wise approach and correct read of the increasing intensity of the scrutiny around rising healthcare costs." Maris continues to expect the " chilling effect" on price increases to spread through the industry. Lastly, the analyst pointed out that the Amgen-partnered (AMGN) launch of Aimovig is off to a strong start, which he believes bodes well for Teva's fremanezumab and Eli Lilly's (LLY) galcanezumab.

TODAY'S FREE FLY STORIES

03:35
05/22/19
05/22
03:35
05/22/19
03:35
General news
FX Action: USD-CAD etched out a 12-day low »

FX Action: USD-CAD etched…

03:05
05/22/19
05/22
03:05
05/22/19
03:05
General news
FX Update: The main currencies have been trading narrow ranges »

FX Update: The main…

02:10
05/22/19
05/22
02:10
05/22/19
02:10
General news
Asian Market Wrap: »

Asian Market Wrap:…

01:45
05/22/19
05/22
01:45
05/22/19
01:45
General news
Fed's Bullard says rate cut could become "attractive option »

Fed's Bullard says…

CVNA

Carvana

$66.99

-0.175 (-0.26%)

21:14
05/21/19
05/21
21:14
05/21/19
21:14
Syndicate
Carvana 4.2M share Secondary priced at $65.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 05

    Jun

  • 18

    Jun

  • 22

    May

INSM

Insmed

$26.37

-1.71 (-6.09%)

20:57
05/21/19
05/21
20:57
05/21/19
20:57
Syndicate
Insmed 9.62M share Secondary priced at $26.00 »

Morgan Stanley, SVB…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 22

    May

LOW

Lowe's

$111.10

1.86 (1.70%)

, ADI

Analog Devices

$99.98

2.54 (2.61%)

20:25
05/21/19
05/21
20:25
05/21/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

LOW

Lowe's

$111.10

1.86 (1.70%)

ADI

Analog Devices

$99.98

2.54 (2.61%)

TGT

Target

$72.05

-0.05 (-0.07%)

VFC

VF Corp.

$92.13

1.43 (1.58%)

AAP

Advance Auto Parts

$161.08

2.42 (1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 29

    May

  • 31

    May

  • 06

    Jun

  • 12

    Jun

  • 18

    Jun

20:25
05/21/19
05/21
20:25
05/21/19
20:25
Conference/Events
CLSA Asian tech analysts to hold an analyst/industry conference call »

Asian Technology Analysts…

SPY

SPDR S&P 500 ETF Trust

$286.50

2.55 (0.90%)

, SPX

S&P 500

$0.00

(0.00%)

20:24
05/21/19
05/21
20:24
05/21/19
20:24
Periodicals
China ambassador to U.S. says Beijing ready to continue talks, Reuters reports »

China ambassador to the…

SPY

SPDR S&P 500 ETF Trust

$286.50

2.55 (0.90%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEO

NeoGenomics

$21.81

-1.38 (-5.95%)

20:12
05/21/19
05/21
20:12
05/21/19
20:12
Syndicate
NeoGenomics 7M share Secondary priced at $21.25 »

Morgan Stanley, SVB…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 05

    Jun

  • 06

    Jun

  • 13

    Nov

  • 23

    May

BAM

Brookfield

$47.03

0.02 (0.04%)

, BX

Blackstone

$41.79

1.17 (2.88%)

19:29
05/21/19
05/21
19:29
05/21/19
19:29
Periodicals
Brookfield, Fortress among bidders for Anbang hotel portfolio, Bloomberg says »

Brookfield Asset…

BAM

Brookfield

$47.03

0.02 (0.04%)

BX

Blackstone

$41.79

1.17 (2.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

  • 08

    Aug

GOLD

Barrick Gold

$12.12

-0.07 (-0.57%)

19:18
05/21/19
05/21
19:18
05/21/19
19:18
Hot Stocks
Barrick says Acacia proposal reflects 'fair value' following Tanzania talks »

Barrick Gold Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SE

Sea Limited

$25.38

-0.42 (-1.63%)

19:04
05/21/19
05/21
19:04
05/21/19
19:04
Hot Stocks
Sea Limited reports Q1 QAUs up 114.4% from last year »

Reports Q1 Quarterly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

SE

Sea Limited

$25.38

-0.42 (-1.63%)

19:02
05/21/19
05/21
19:02
05/21/19
19:02
Earnings
Sea Limited reports Q1 EPS (64c), consensus (68c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

SNE

Sony

$51.01

-1.195 (-2.29%)

18:48
05/21/19
05/21
18:48
05/21/19
18:48
Periodicals
Sony aims to bolster cash flow to better compete in chips, games, NAR says »

Sony is seeking to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jun

OOMA

Ooma

$14.49

-0.45 (-3.01%)

, CVI

CVR Energy

$47.29

0.9 (1.94%)

18:47
05/21/19
05/21
18:47
05/21/19
18:47
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Ooma…

OOMA

Ooma

$14.49

-0.45 (-3.01%)

CVI

CVR Energy

$47.29

0.9 (1.94%)

PVH

PVH Corp.

$108.53

2.5075 (2.37%)

PSTG

Pure Storage

$20.60

0.6 (3.00%)

JWN

Nordstrom

$37.88

0.42 (1.12%)

URBN

Urban Outfitters

$27.01

0.05 (0.19%)

TOL

Toll Brothers

$38.34

0.82 (2.19%)

ONCS

OncoSec

$3.95

0.149 (3.92%)

EKSO

Ekso Bionics

$1.84

-0.06 (-3.16%)

TOCA

Tocagen

$8.81

-0.18 (-2.00%)

LIQT

LiqTech

$9.29

-0.21 (-2.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 23

    May

  • 28

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 03

    Jun

  • 04

    Jun

  • 05

    Jun

  • 06

    Jun

  • 10

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 09

    Jul

  • 22

    May

  • 22

    May

  • 22

    May

TREX

Trex Company

$61.44

2.38 (4.03%)

18:45
05/21/19
05/21
18:45
05/21/19
18:45
Hot Stocks
Trex Company CEO: There is no demand issue »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CRMT

America's Car-Mart

$101.76

1.74 (1.74%)

18:34
05/21/19
05/21
18:34
05/21/19
18:34
Earnings
America's Car-Mart reports Q4 EPS $2.07, consensus $1.82 »

Reports Q4 revenue $177M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 30

    May

  • 13

    Nov

JCOM

j2 Global

$87.23

0.75 (0.87%)

18:25
05/21/19
05/21
18:25
05/21/19
18:25
Hot Stocks
j2 Global CFO sells 5.6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 22

    May

  • 05

    Jun

NVS

Novartis

$82.38

0.36 (0.44%)

18:24
05/21/19
05/21
18:24
05/21/19
18:24
Hot Stocks
Novartis CEO: We are entering an exciting growth phase for the company »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 31

    May

EADSY

Airbus

$0.00

(0.00%)

18:20
05/21/19
05/21
18:20
05/21/19
18:20
Periodicals
Airbus in talks to find resolution to German arms export row, Reuters says »

Airbus CEO Guillaume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGRO

Adecogro

$6.50

0.07 (1.09%)

18:19
05/21/19
05/21
18:19
05/21/19
18:19
Earnings
Adecogro reports Q1 adjusted EBITDA $58.3M, down 5.9% from last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,149.14

10.81 (0.95%)

, GOOGL

Alphabet Class A

$1,154.26

8.98 (0.78%)

18:01
05/21/19
05/21
18:01
05/21/19
18:01
Hot Stocks
Google updates policy on abortion-related ads »

Google said in a post…

GOOG

Alphabet

$1,149.14

10.81 (0.95%)

GOOGL

Alphabet Class A

$1,154.26

8.98 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 19

    Jun

  • 27

    Oct

HAIN

Hain Celestial

$23.90

0.45 (1.92%)

17:50
05/21/19
05/21
17:50
05/21/19
17:50
Hot Stocks
Engaged Capital raises stake in Hain Celestial to 20.2% from 18.3% »

Engaged Capital raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTDOY

Nintendo

$0.00

(0.00%)

17:48
05/21/19
05/21
17:48
05/21/19
17:48
Hot Stocks
Nintendo to end 'Animal Crossing,' 'Fire Emblem' mobile game service in Belgium »

Nintendo announced that,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jun

  • 11

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.